BP
ABCL icon

Ballentine Partners’s AbCellera Biologics ABCL Stock Holding History

Ballentine Partners’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$146K Sell
18,656
-649
-3% -$3.17K ﹤0.01% 1032
2026
Q1 		$67.4K Buy
19,305
+702
+4% +$2.53K ﹤0.01% 995
2025
Q4 		$63.6K Sell
18,603
-6,408
-26% -$28.6K ﹤0.01% 986
2025
Q3 		$126K Buy
25,011
+1,322
+6% +$5.83K ﹤0.01% 966
2025
Q2 		$81.3K Buy
+23,689
New +$59K ﹤0.01% 950
2025
Q1 		– Sell
-19,942
Closed -$58.4K – 912
2024
Q4 		$58.4K Sell
19,942
-790
-4% -$2.2K ﹤0.01% 868
2024
Q3 		$53.9K Buy
+20,732
New +$57.4K ﹤0.01% 832

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Ballentine Partners's ABCL Position: Q2 2026 in Review

Ballentine Partners reduced its AbCellera Biologics (ABCL) stake by 3.4% in Q2 2026, selling an estimated $3.17K and leaving 18,656 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #1032.

Ballentine Partners first reported a position in ABCL in Q3 2024 and has held it in 7 quarters since. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Ballentine Partners held 18,656 shares of AbCellera Biologics worth $146K as of Q2 2026.
  • Ballentine Partners sold 649 AbCellera Biologics shares in Q2 2026, an estimated $3.17K.
  • AbCellera Biologics made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #1032 holding.
  • Ballentine Partners first reported a position in AbCellera Biologics in Q3 2024 and has held it in 7 quarters since.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.